Clinical Trial

Safety & Efficacy of Baclofen for Alcohol Withdrawal in Chronic Liver Disease With Active Alcohol Consumption

Study acronym: BAWIC
Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated February 21, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
This study examines the safety and effectiveness of baclofen as a treatment for alcohol withdrawal in patients with chronic liver disease who continue drinking. It aims to evaluate baclofen's ability to promote alcohol abstinence or reduction while monitoring adverse effects. Secondary outcomes include liver function changes, hospital readmissions, and complications of cirrhosis. Alcohol consumption worsens liver disease prognosis, yet alcohol use disorder (AUD) often goes untreated. Baclofen, which is safe for patients with liver impairment, is recommended as a first-line treatment for AUD in chronic liver disease. This prospective study collects data from patients treated with baclofen at Parc Taulí Hospital, analyzing outcomes at three and six months to assess abstinence, alcohol reduction, and adverse effects.
Trial Details
NCT Number NCT06840652
Lead Sponsor Corporacion Parc Tauli
Conditions Alcoholic Cirrhosis, Alcohol Abstinence, Alcohol Withdrawal, Medication Toxicity, Medication Adherence
Enrollment 120 participants
Start Date 2022-12-22
Primary Completion 2026-01 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2025-02-21